2E,6E,10E-geranylgeranyl p-toluenesulfonate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2E,6E,10E-geranylgeranyl p-toluenesulfonate
• 英文别名: [(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl] 4-methylbenzenesulfonate
• 化学式: C₂₇H₄₀O₃S
• 分子量: 444.679
• InChiKey: GXJLJIDOMGRGBU-NHLAYJJJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.6
• 重原子数：
  31
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2E,6E,10E-geranylgeranyl p-toluenesulfonate 在 正丁基锂 、 lithium 、 乙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 9.0h， 生成 3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-ol
  参考文献：
  名称：

  Novel Regio- and Stereoselective Cascade 6-endo-trig Cyclisations from Polyene Acyl Radical Intermediates Leading to Steroid-Like Pentacycles and Heptacycles

  摘要：

  In a quite remarkable regio- and stereoselective manner, each of the (all-E)-polyene selenoates 5a-c is shown to undergo cascade radical-mediated polycyclisations via consecutive 6-endo-trig reactions, leading to the corresponding all-trans, anti, tri-, penta- and heptacycles, i.e., 20, 23, and 25, in good yields. The configurations of these 'steroid-like' polycycles followed from detailed examination and correlation of chemical shift data in their C-13-NMR spectra.

  DOI：

  10.1002/1522-2675(20000906)83:9<2629::aid-hlca2629>3.0.co;2-w
• 作为产物：
  描述：

  香叶基香叶醇 、 对甲苯磺酰氯 在 N,N-二甲基丙烯基脲 、 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 3.0h， 生成 2E,6E,10E-geranylgeranyl p-toluenesulfonate
  参考文献：
  名称：

  Novel Regio- and Stereoselective Cascade 6-endo-trig Cyclisations from Polyene Acyl Radical Intermediates Leading to Steroid-Like Pentacycles and Heptacycles

  摘要：

  In a quite remarkable regio- and stereoselective manner, each of the (all-E)-polyene selenoates 5a-c is shown to undergo cascade radical-mediated polycyclisations via consecutive 6-endo-trig reactions, leading to the corresponding all-trans, anti, tri-, penta- and heptacycles, i.e., 20, 23, and 25, in good yields. The configurations of these 'steroid-like' polycycles followed from detailed examination and correlation of chemical shift data in their C-13-NMR spectra.

  DOI：

  10.1002/1522-2675(20000906)83:9<2629::aid-hlca2629>3.0.co;2-w

文献信息

• [EN] GGA AND GGA DERIVATIVES, COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM<br/>[FR] GGA ET DÉRIVÉS DE GGA, COMPOSITIONS DE CEUX-CI ET PROCÉDÉS POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES, COMPRENANT UNE PARALYSIE, LES COMPRENANT
  申请人：COYOTE PHARMACEUTICALS INC

  公开号：WO2013130654A1

  公开（公告）日：2013-09-06

  This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

  本发明涉及戈芬酯醋酸酯（GGA）衍生物以及在抑制神经细胞死亡、增加神经活性、促进轴突生长和细胞存活能力，以及提高接受GGA或GGA衍生物的受试者的存活率的方法中使用GGA及其异构体和GGA衍生物。
• [EN] GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM<br/>[FR] GGA ET DÉRIVÉS DE GGA, COMPOSITIONS DE CEUX-CI ET MÉTHODES POUR TRAITER DES MALADIES NEURODÉGÉNÉRATIVES, Y COMPRIS LA PARALYSIE, EN LES UTILISANT
  申请人：COYOTE PHARMACEUTICALS INC

  公开号：WO2014163643A1

  公开（公告）日：2014-10-09

  This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

  本发明涉及香叶醇丙酮（GGA）衍生物以及在抑制神经细胞死亡、增加神经活性、促进轴突生长和细胞存活能力，以及提高接受GGA或GGA衍生物的受试者的存活率的方法中使用GGA、其异构体和GGA衍生物。
• GERANYLGERANYLACETONE DERIVATIVES
  申请人：Serizawa Hiroaki

  公开号：US20130085283A1

  公开（公告）日：2013-04-04

  Provided herein are geranylgeranylacetone derivatives and methods of using them.

  本文提供了戊二烯基乙酮衍生物及其使用方法。
• GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM
  申请人：COYOTE PHARMACEUTICALS, INC.

  公开号：US20130296323A1

  公开（公告）日：2013-11-07

  This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

  本发明涉及葛兰醇醚酮（GGA）衍生物及其使用，包括GGA、其异构体和GGA衍生物在抑制神经细胞死亡、增加神经活动、增加轴突生长和细胞存活率以及提高接受GGA或GGA衍生物的主体的生存率的方法中的应用。
• PREVENTIVE/REMEDY FOR LIVER DISEASE
  申请人：NISSHIN FLOUR MILLING CO., LTD.

  公开号：EP0810201A1

  公开（公告）日：1997-12-03

  Hepatic diseases can be prevented or treated by administering an isoprenylamine derivative represented by the general formula (II) [wherein n represents an integer of 4 - 12, m represents an integer of 0 - 3, Ar represents a phenyl group, a furyl group, a thienyl group or a pyridyl group, said group being optionally substituted with one or more of an alkyl group of 1 - 4 carbon atoms, and alkoxy group of 1 - 4 carbon atoms, a methylenedioxy group, a hydroxy group or a halogen atom, and R represents a hydrogen atom or an alkyl group of 1 - 4 carbon atoms] or a pharmacologically acceptable salt thereof at a daily dose of 0.01 - 500 µg/kg. A lipid emulsion of the compound (II) is particularly useful and can be administered at a remarkably lowered dose as compared with other pharmaceutical preparations.

  通过施用通式 (II) 所代表的异戊胺衍生物，可以预防或治疗肝病。 [其中 n 代表 4 - 12 的整数，m 代表 0 - 3 的整数，Ar 代表苯基、呋喃基、噻吩基或吡啶基，所述基团任选被 1 - 4 个碳原子的烷基、1 - 4 个碳原子的烷氧基、亚甲基二氧基、羟基或卤原子中的一个或多个取代，R 代表氢原子或 1 - 4 个碳原子的烷基]或其药理学上可接受的盐，每日剂量为 0.01 - 500 µg/kg。 化合物（II）的脂质乳剂特别有用，与其他药物制剂相比，其给药剂量明显降低。